



## Rezpegaldesleukin Shows Durable Responses in AD


Rezpegaldesleukin (Nektar Therapeutics) maintained or improved atopic dermatitis outcomes over 52 weeks in the Phase 2b REZOLVE-AD study. Both monthly and quarterly dosing sustained key efficacy measures with a safety profile consistent with prior results.

[Read More](#)

## Arcutis Starts Phase 1 Trial of ARQ-234

Arcutis (ARQ-234) has begun a Phase 1a/1b study to assess safety and tolerability in healthy adults and those with moderate to severe atopic dermatitis. The study will evaluate single- and multiple-dose regimens and includes a small proof-of-concept cohort in patients with atopic dermatitis.

[Read the Announcement](#)



## Nemolizumab Maintains Long-Term Control in Prurigo Nodularis

Galderma's Nemluvio® (nemolizumab) showed sustained improvements in itch, skin lesions, and quality of life for up to three years in prurigo nodularis patients. The treatment's safety profile remained consistent throughout the study.

[Read the Press Release](#)

## Denifanstat Shows Favorable Safety in Phase III Acne Study

Ascleptis Pharma's denifanstat (ASC40), a once-daily oral FASN inhibitor, was well tolerated in a Phase 3 open-label study of 240 patients with moderate-to-severe acne. The results support its safety profile and align with prior efficacy data from a placebo-controlled Phase 3 trial.

[Learn More](#)

## Kyowa Kirin Discontinues Rocatinlimab Trials

Kyowa Kirin's rocatinlimab, an anti-OX40 monoclonal antibody, will no longer advance in clinical trials for atopic dermatitis, uncontrolled asthma, and prurigo nodularis following a recent safety review.

[Learn More](#)

## AbbVie Submits Applications for Upadacitinib in Vitiligo

AbbVie submitted applications to the FDA and EMA for upadacitinib (RINVOQ®) to treat adults and adolescents with non-segmental vitiligo. The filings are supported by Phase 3 Viti-Up studies showing improvements in total body and facial re-pigmentation after 48 weeks.

[Learn More](#)

## CPE Spotlight



The following highlights select engagements and programs supported by CPE over the past month.

### Advisory Board Meeting

Delivered logistics support for a dermatology-focused in-person advisory board meeting

- 2026 Winter Clinical Miami – Aventura, Florida

Below is a list of CPE's core service offerings for clients across marketing and medical affairs. While these reflect our core capabilities, our team regularly customizes solutions to meet evolving client needs.

#### Medical Affairs

- Asynchronous Engagements
- KOL Identification & Contracting
- MOA Visualization
- MSL Training
- Patient Education
- Poster Presentations
- Scientific Platform Development

#### Medical Affairs + Marketing

- Advisory Boards (Virtual or In-Person)
- Conference Planning
- Content Development
- Core Slide Decks
- KOL Engagements
- Publications

#### Marketing

- Branding & Visual Aids
- Healthcare Event Production Management
- Launch Preparation
- Product Theater Planning & Logistics
- Speaker Bureau Services
- Speaker Training
- Technical Productions

*CPE partners across the product lifecycle to drive results through KOL engagement, advisory boards, content, and marketing.*

*Let's connect to review a customized overview of our capabilities and discuss how we could work together.*

With appreciation,

Allison Goldberg, MPA  
Associate Vice President  
CPE Communications  
Cell: 917-509-9583  
[agoldberg@cpeducate.com](mailto:agoldberg@cpeducate.com)

When you're ready to explore how the CPE Communications Team can support your team, contact Allison at [agoldberg@cpeducate.com](mailto:agoldberg@cpeducate.com)

